Why Coya Therapeutics, Inc.’s (COYA) Stock Is Up 8.61%
As of Wednesday, November 18, Coya Therapeutics, Inc.’s COYA share price has surged by 8.61%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Jenna Brashear
Jenna Brashear
Rosalio Madrigal
Rosalio Madrigal
| Share Statistics | COYA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $69.9 | $212.8 | 20% |
|
| Shares Out (Mil) | 23.5 | 55.2 | 33% |
|
| Institutional Ownership | 79.5% | 93.3% | 48% |
|
| Float (Mil) | 17.5 | 40.8 | 27% |
|
| Beta | 0.70 | 1.03 | 40% |
|
| Avg Daily Volume (000s) | 153 | 559 | 41% |
|
| Price Change (52-week) |
(51.6%) | 40.3% | 20% |
|
| Growth | COYA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (97.8%) | (10.5%) | 2% |
|
| EPS (5yr) | (16.2%) | 15.4% | 17 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (41.1%) | (15.7%) | 11% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.483) | ($1.537) | ($2.023) | |
| Month Ago EPS | ($0.380) | ($1.367) | ($1.920) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.360) | ($1.420) | ($1.725) | |
| Year/Year Chg | 6.6% | 21.1% | (7.4%) | |
| Financials | COYA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $5 | $40 | 5% |
|
| Net Income (TTM) (Mil) | ($30) | ($44) | 20% |
|
| EPS (TTM) | ($1.398) | ($1.400) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($22) | ($34) | 14% |
|
| Net Cash Flow (TTM) (Mil) | $8 | $-0 | 56% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $35 | $142 | 15% |
|
| Valuation | COYA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.08 | 1.97 | 59% |
|
| P/E | na | 16.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | COYA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (382.8%) | 67.6% | 1% |
|
| Net Margin | (643.5%) | (50.8%) | 1% |
|
| ROA | (84.6%) | (47.4%) | 6% |
|
| ROE | (99.2%) | (51.4%) | 9% |
|
| Liabilities to Assets | 14.6% | 29.6% | 9% |
|
| F-Score | 2 | 3 | 7% |
|
Coya Therapeutics, Inc. did not pass any screens on 11/19/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors